Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.79 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.79 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.71 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.67 |
| ▸ | GAA | P10253 | 2/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3397385 | 0.89 | MEN1 (0.81) | MEN1KMT2APDE1CADORA2BGAA | |
| SCHEMBL3397010 | 0.88 | KIF11 (0.76) | MEN1KMT2APDE1CADORA2BGAA | |
| SCHEMBL13425331 | 0.87 | MEN1 (0.67) | MEN1KMT2APDE1CTDP1ADORA2B | |
| SCHEMBL13425510 | 0.87 | PDE1C (0.74) | MEN1KMT2APDE1CTDP1ADORA2B | |
| SCHEMBL3399108 | 0.86 | PDE1C (0.81) | MEN1KMT2APDE1CTDP1ADORA2B | |
| SCHEMBL3395577 | 0.86 | PDE1C (0.82) | MEN1KMT2APDE1CADORA2BGAA | |
| SCHEMBL3435823 | 0.85 | MEN1 (0.65) | MEN1KMT2APDE1CTDP1ADORA2B | |
| SCHEMBL18025267 | 0.85 | KIF11 (0.75) | ADORA2BPOLB | |
| SCHEMBL5347891 | 0.85 | KIF11 (0.75) | ADORA2BPOLB | |
| SCHEMBL19752667 | 0.85 | KIF11 (0.75) | ADORA2BPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010046780-A2 | ANTI VIRAL COMPOUNDS | INSTITUT PASTEUR KOREA (KR) | 2010-04-29 | — | — | WO | disclosed |
| WO-2010046780-A2 | ANTI VIRAL COMPOUNDS | INSTITUT PASTEUR KOREA (KR) | 2010-04-29 | — | — | WO | disclosed |